Opportunity Information: Apply for RFA HG 15 001
Apply for RFA HG 15 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Centers for Common Disease Genomics (UM1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172 Human Genome Research.
- This funding opportunity was created on Dec 12, 2014 and posted on Dec 12, 2014.
- Applicants must submit their applications by Apr 7, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $60,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $40,000,000.00 in funding.
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Small businesses County governments State governments Private institutions of higher education For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Centers for Common Disease Genomics (UM1) funding opportunity (RFA-HG-15-001) is a National Institutes of Health initiative led by the National Human Genome Research Institute (NHGRI) to support a coordinated, large-scale genome sequencing program focused on common diseases. The core purpose is to discover and characterize rare genetic variants that either increase disease risk or provide protection across multiple common disease phenotypes. Rather than concentrating on a single disorder, the program is designed to sample a broad range of diseases and study designs so that researchers can compare different "disease architectures" and learn generalizable rules about how inherited genetic variation contributes to complex, multifactorial conditions.
A major theme of the opportunity is comprehensive rare-variant discovery at scale. The emphasis on rare risk and protective variants reflects an interest in the part of the allele frequency spectrum that is often missed or underpowered in many traditional genetic studies, yet can yield large biological insights and more direct links to molecular mechanisms. By sequencing large cohorts and applying consistent analytic approaches, the program aims to improve understanding of how rare variants shape susceptibility to common diseases, what kinds of variants matter most (for example, coding, regulatory, or structural variation), and how these findings differ across diseases with distinct genetic architectures.
Beyond generating variant catalogs, the initiative is explicitly about learning how to design better rare-variant studies for common disease. This includes comparing alternative study designs (such as case-control cohorts, extreme-phenotype sampling, family-based designs, and population-based biobanks), exploring how sample size, ancestry diversity, phenotyping depth, and sequencing strategy affect discovery, and developing best practices for analysis and interpretation. The intent is that, by examining enough different examples, the program can offer practical guidance that other disease research communities can reuse rather than forcing each field to reinvent methods from scratch.
The award mechanism is a UM1 cooperative agreement, which signals substantial NIH programmatic involvement and coordination across funded sites. In practice, this kind of mechanism is used when the agency expects active collaboration among awardees, shared standards, harmonized data generation and analysis pipelines, and joint production of community resources. The program is framed as a set of "Centers," implying multi-investigator, multi-component efforts with capacity for high-throughput sequencing, rigorous quality control, phenotype integration, and advanced statistical and computational genetics.
Another central deliverable is the creation of broadly useful resources for the biomedical community. The solicitation highlights development of informatics tools, analytic resources, and innovative approaches and technologies that can support multiple disease areas, not just the conditions directly studied by the Centers. This can include scalable variant-calling and annotation workflows, methods for rare-variant aggregation tests, approaches for integrating sequencing data with clinical and phenotypic information, strategies for dealing with population structure and relatedness, and frameworks for sharing data and results in ways that accelerate downstream research. The overall goal is to strengthen infrastructure for genomic discovery and translation across many fields.
From an administrative standpoint, the opportunity is classified as discretionary funding and falls under the health activity category, with CFDA number 93.172 (Human Genome Research). The posting date and creation date were December 12, 2014, with an original and current closing date of April 7, 2015, and an archive date of May 8, 2015. The estimated total funding amount listed is $60,000,000, with an award ceiling of $40,000,000, indicating the program expected a small number of large, center-scale awards rather than many smaller grants. There is no cost sharing or matching requirement.
Eligibility is broad and includes many U.S.-based organization types: public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), state, county, city, township, and special district governments, tribal governments and tribal organizations, public housing authorities, independent school districts, small businesses, and for-profit organizations other than small businesses. The eligibility language also explicitly calls out a variety of institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions, as well as faith-based and community-based organizations and eligible federal agencies. At the same time, non-U.S. entities (foreign organizations and foreign institutions) are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply; however, foreign components, as defined in the NIH Grants Policy Statement, are allowed, which typically means certain discrete project components can be performed abroad when well-justified and compliant with NIH policy.
The full announcement was made available through an NIH grants guide link (http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-15-001.html). For technical issues accessing or linking to the announcement, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs)
What is the Centers for Common Disease Genomics (UM1) opportunity?
The Centers for Common Disease Genomics (UM1) opportunity (RFA-HG-15-001) is a National Institutes of Health (NIH) initiative led by the National Human Genome Research Institute (NHGRI) to support a coordinated, large-scale genome sequencing program focused on common diseases. It is structured as a set of "Centers" intended to work in a coordinated way across multiple disease areas.
What is the main scientific purpose of this program?
The core purpose is to discover and characterize rare genetic variants that either increase risk or provide protection across multiple common disease phenotypes. A key goal is to understand how inherited genetic variation contributes to complex, multifactorial conditions and to compare different genetic "disease architectures" across diseases.
Does the program focus on one specific disease?
No. The program is designed to sample a broad range of common diseases and study designs rather than concentrating on a single disorder. This breadth is intended to enable comparisons across diseases and help develop generalizable principles.
What kinds of genetic variants are emphasized?
The opportunity emphasizes comprehensive discovery of rare variants at scale, including rare variants that increase disease risk and rare variants that are protective. The program also aims to improve understanding of what kinds of variants matter most, such as coding variation, regulatory variation, or structural variation, and how their relevance may differ by disease.
Why is there a strong focus on rare variants?
Rare variants are highlighted because they are often missed or underpowered in many traditional genetic studies, yet they can yield substantial biological insight and more direct connections to underlying molecular mechanisms.
What types of study designs are relevant to this opportunity?
The initiative explicitly mentions comparing alternative rare-variant study designs, including case-control cohorts, extreme-phenotype sampling, family-based designs, and population-based biobanks. It also stresses learning how design choices affect rare-variant discovery.
What methodological questions is the program trying to answer?
Beyond generating catalogs of variants, the program aims to learn how to design better rare-variant studies for common diseases. It includes exploring how factors like sample size, ancestry diversity, phenotyping depth, and sequencing strategy influence discovery, and developing best practices for analysis and interpretation.
What does the UM1 cooperative agreement mechanism mean for applicants and awardees?
UM1 is a cooperative agreement mechanism, which indicates substantial NIH programmatic involvement. This mechanism is typically used when NIH expects active coordination among awardees, shared standards, harmonized data generation and analysis pipelines, and collaborative development of community resources.
What kinds of capabilities are implied by the "Centers" model?
The "Centers" framing implies multi-investigator, multi-component efforts with the capacity for high-throughput sequencing, rigorous quality control, phenotype integration, and advanced statistical and computational genetics, coordinated across sites.
What types of deliverables and community resources are expected?
The solicitation highlights creation of broadly useful resources for the biomedical community. These include development of informatics tools, analytic resources, and innovative approaches and technologies that can support multiple disease areas, not only the diseases directly studied by the Centers.
What are examples of tools or methods the initiative aims to develop or improve?
Examples described include scalable variant-calling and annotation workflows, methods for rare-variant aggregation tests, approaches for integrating sequencing data with clinical and phenotypic information, strategies for handling population structure and relatedness, and frameworks for sharing data and results to accelerate downstream research.
What NIH institute is leading this initiative?
The initiative is led by the National Human Genome Research Institute (NHGRI) within NIH.
What is the funding mechanism and is this discretionary funding?
The award mechanism is UM1 (cooperative agreement). The opportunity is classified as discretionary funding and falls under the health activity category.
What is the CFDA number for this opportunity?
The CFDA number listed is 93.172 (Human Genome Research).
How much funding is available and what does it suggest about the program size?
The estimated total funding amount listed is $60,000,000, with an award ceiling of $40,000,000. This suggests the program expected a small number of large, center-scale awards rather than many smaller grants.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organization types, including public and private institutions of higher education; nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits); state, county, city, township, and special district governments; tribal governments and tribal organizations; public housing authorities; independent school districts; small businesses; and for-profit organizations other than small businesses.
Are minority-serving institutions and community-based organizations included in the eligible entity types?
Yes. The eligibility language explicitly calls out a variety of institution types including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions, as well as faith-based and community-based organizations, and eligible federal agencies.
Are foreign organizations or non-U.S. institutions eligible to apply?
No. Non-U.S. entities (foreign organizations and foreign institutions) are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. The opportunity states that non-U.S. components of U.S. organizations are not eligible to apply.
Are any foreign activities allowed at all?
Yes, foreign components (as defined in the NIH Grants Policy Statement) are allowed. This typically means specific, discrete components of a project may be performed abroad when well-justified and compliant with NIH policy.
What are the key dates for this opportunity?
The posting date and creation date were December 12, 2014. The original and current closing date was April 7, 2015. The archive date was May 8, 2015.
Where can the full funding announcement be found?
The full announcement is available through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-15-001.html
Who should be contacted for technical issues accessing or linking to the announcement?
For technical issues accessing or linking to the announcement, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What is the official identifier for this funding opportunity?
The opportunity is identified as RFA-HG-15-001, titled Centers for Common Disease Genomics (UM1).
Browse more opportunities from the same category: Health
Next opportunity: FY15 FY16 Department of Defense HIV/AIDS Prevention Program Military Specific HIV/AIDS Prevention, Care, and Treatment Program for PEPFAR (Presidents Emergency Plan for AIDS Relief) Funded Countries
Previous opportunity: FY 2015 Polar Bear Co management
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 15 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 15 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| FY15 FY16 Department of Defense HIV/AIDS Prevention Program Military Specific HIV/AIDS Prevention, Care, and Treatment Program for PEPFAR (Presidents Emergency Plan for AIDS Relief) Funded Countries Apply for DHAPP BAA 15 002 Funding Number: DHAPP BAA 15 002 Agency: Naval Supply Systems Command Category: Health Funding Amount: Case Dependent |
| Centers for Mendelian Genomics (UM1) Apply for RFA HG 15 002 Funding Number: RFA HG 15 002 Agency: National Institutes of Health Category: Health Funding Amount: $5,000,000 |
| Strengthening Clinical and Laboratory Services at the National Referral Level to Improve HIV Prevention, Care, and Treatment in the Republic of Zambia under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1603 Funding Number: CDC RFA GH15 1603 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $27,475,000 |
| Geriatrics Workforce Enhancement Program Apply for HRSA 15 057 Funding Number: HRSA 15 057 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Childrens Safety Network Program Apply for HRSA 15 067 Funding Number: HRSA 15 067 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Coordinating Center for the Regional Genetic Service Collaboratives Apply for HRSA 15 081 Funding Number: HRSA 15 081 Agency: Health Resources and Services Administration Category: Health Funding Amount: $800,000 |
| Strengthening the Delivery and Expanding Access to Quality Laboratory Services and Enhancing Healthcare Worker and Laboratory Safety in the Republic of South Africa under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1575 Funding Number: CDC RFA GH15 1575 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Support the Strengthening and Utilization of Strategic Information Activities in the Republic of South Africa under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1576 Funding Number: CDC RFA GH15 1576 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $25,000,000 |
| Investigational New Drug (IND) enabling Development of Medications to Treat Alcohol Use Disorder and Alcohol related Disorders (UT2) Apply for PAR 15 073 Funding Number: PAR 15 073 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Investigational New Drug (IND) enabling Development of Medications to Treat Alcohol Use Disorder and Alcohol related Disorders (U44) Apply for PAR 15 074 Funding Number: PAR 15 074 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Evaluating Innovative and Promising Strategies to Prevent Suicide among Middle Aged Men Apply for RFA CE 15 004 Funding Number: RFA CE 15 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $330,000 |
| Establish a Vision and Eye Health Surveillance System for the Nation Apply for RFA DP 15 004 Funding Number: RFA DP 15 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Research Projects (U01) Apply for RFA AA 15 004 Funding Number: RFA AA 15 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Administrative Resource (U24) Apply for RFA AA 15 005 Funding Number: RFA AA 15 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Research Resource (U24) Apply for RFA AA 15 006 Funding Number: RFA AA 15 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Investigating New Approaches for Tobacco Surveillance Systems Apply for RFA DP 15 006 Funding Number: RFA DP 15 006 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $700,000 |
| NIAMS Skin Biology and Diseases Resource based Centers (P30) Apply for RFA AR 16 003 Funding Number: RFA AR 16 003 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Strategic Prevention Framework Partnerships for Success State and Tribal Initiative (SPF PFS) Apply for SP 15 003 Funding Number: SP 15 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $2,472,608 |
| Program Expansion Supplement for Advancing National Public Health Institutes Globally Apply for CDC RFA GH14 14190302SUPP15 Funding Number: CDC RFA GH14 14190302SUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $30,000,000 |
| National Public Health Practice and Resource Centers on Health Promotion for People with Disabilities DD12 1205 Apply for CDC RFA DD15 1509 Funding Number: CDC RFA DD15 1509 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 15 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.